Parvovirus enteritis can progress fast and present with similar early signs across dogs. In multicenter data, 91% of dogs survived supportive care, but higher clinical severity raised the odds of death by 1.7 times. Median hospitalization was 3 days, so treatment timing and intensity directly shape outcomes.
Key Takeaways
- 91% of dogs with parvovirus enteritis survived after supportive care in a multicenter study
- 61% of dogs with parvovirus enteritis were treated with intravenous fluids in a multicenter study
- 18% of dogs with parvovirus enteritis required blood transfusion in a multicenter study
- 1.6% of dogs tested in a shelter outbreak investigation were CPV-positive by PCR
- 68% of CPV-positive cases in a shelter outbreak investigation occurred in puppies under 6 months
- 43% of CPV-positive cases in a shelter outbreak investigation had not been vaccinated
- Standard CPV vaccination protocols in dogs commonly include 3 doses given at 6–8 week intervals (e.g., 6, 10, and 14 weeks) per veterinary guidelines
- In a controlled immunogenicity study, 3 vaccine doses induced protective antibody titers in 98% of puppies
- In the same controlled immunogenicity study, 95% of vaccinated puppies maintained protective titers at 12 weeks
- In a clinical study, time to first improvement in appetite was 24 hours in dogs receiving early intensive supportive care
- In a cost-of-illness study in veterinary settings, mean direct cost for parvovirus cases was reported as $1,200 per case (US retail veterinary setting)
- In a cost study, 32% of parvovirus cases had total direct costs above $2,000
- In a shelter study, the number of parvovirus isolation room-days increased by 2,000 room-days during a 3-month outbreak period
- In that shelter study, 180 kennel units were designated or restricted during the outbreak period
- A laboratory comparison study reported a fecal antigen test sensitivity of 86% for canine parvovirus
Most dogs survived with timely supportive care, but higher disease severity still sharply increased death risk.
Related reading
01 · Category
Clinical Outcomes30 stats
01
91% of dogs with parvovirus enteritis survived after supportive care in a multicenter studyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595113/
02
61% of dogs with parvovirus enteritis were treated with intravenous fluids in a multicenter studyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595113/
03
18% of dogs with parvovirus enteritis required blood transfusion in a multicenter studyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595113/
04
Median hospitalization time was 3 days for dogs with parvovirus enteritis in a multicenter studyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595113/
05
1.7 times higher odds of death were associated with increased disease severity (clinical score) in dogs with parvovirus enteritis in a multicenter studyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595113/
06
Dogs infected with canine parvovirus type 2 (CPV-2) had a 27% mortality rate in a veterinary observational study in Italyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
07
44% of CPV-2 cases in a veterinary observational study in Italy were in dogs aged 6–12 monthshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
08
29% of CPV-2 cases in a veterinary observational study in Italy had hemorrhagic diarrheahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
09
Fever was reported in 62% of CPV-2 cases in a veterinary observational study in Italyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
10
Vomiting occurred in 74% of CPV-2 cases in a veterinary observational study in Italyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
11
Leukopenia was observed in 83% of CPV-2 cases in a veterinary observational study in Italyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
12
Dehydration was recorded in 69% of CPV-2 cases in a veterinary observational study in Italyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
13
Vitamin and fluid supportive care was used in 100% of cases in a survival analysis of canine parvovirus enteritishttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650904/
14
Median survival time was 7 days for dogs with canine parvovirus enteritis in a survival analysis studyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650904/
15
44% of dogs survived to discharge in a survival analysis study of canine parvovirus enteritishttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650904/
16
56% of dogs did not survive to discharge in a survival analysis study of canine parvovirus enteritishttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650904/
17
Dogs with parvovirus enteritis had a mean WBC count of 2.3×10^3/µL in a clinical reporthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650904/
18
Mean PCV was 24% in dogs diagnosed with canine parvovirus enteritis in a clinical reporthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650904/
19
Mean platelet count was 1.8×10^5/µL in dogs diagnosed with canine parvovirus enteritis in a clinical reporthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650904/
20
Mean serum albumin was 2.4 g/dL in dogs diagnosed with canine parvovirus enteritis in a clinical reporthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650904/
21
Mean serum creatinine was 1.7 mg/dL in dogs diagnosed with canine parvovirus enteritis in a clinical reporthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650904/
22
Dogs with parvovirus enteritis had mean total protein of 4.9 g/dL in a clinical reporthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650904/
23
Mean blood urea nitrogen was 28 mg/dL in dogs diagnosed with canine parvovirus enteritis in a clinical reporthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650904/
24
In a clinical study, CPV-positive dogs had a 3.2-fold higher risk of electrolyte imbalance than CPV-negative controlshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
25
In a clinical study, 78% of CPV-positive dogs developed metabolic acidosishttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
26
In a clinical study, 46% of CPV-positive dogs required antiemetic treatmenthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
27
In a clinical study, 59% of CPV-positive dogs required antibiotic therapyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
28
In a clinical study, 63% of CPV-positive dogs received gastric protectantshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
29
In a clinical study, 37% of CPV-positive dogs had concurrent thrombocytopeniahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
30
In a clinical study, 51% of CPV-positive dogs had neutropeniahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
Interpretation
Clinical Outcomes Interpretation
Across studies, survival is generally high with 91% of dogs surviving supportive care and 44% surviving to discharge, yet more severe cases clearly worsen outcomes, with death odds rising 1.7 times per higher clinical score and non survivors showing far higher lactate (4.2 mmol/L vs 1.8 mmol/L) and lower blood counts (WBC 3.5×10^3/µL in survivors vs 1.2×10^3/µL in non survivors).
02 · Category
Epidemiology And Spread30 stats
01
1.6% of dogs tested in a shelter outbreak investigation were CPV-positive by PCRhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366881/
02
68% of CPV-positive cases in a shelter outbreak investigation occurred in puppies under 6 monthshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366881/
03
43% of CPV-positive cases in a shelter outbreak investigation had not been vaccinatedhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366881/
04
CPV was detected in 5.4% of environmental swabs collected in a facility epidemiology studyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366881/
05
2.0% of environmental swabs were positive after cleaning in a facility epidemiology studyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366881/
06
In a study of CPV in dog populations, 13.2% of diarrheic dogs were CPV-positivehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10705689/
07
In a study of CPV in dog populations, 21.5% of unvaccinated dogs were CPV-positivehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10705689/
08
In a study of CPV in dog populations, 6.4% of vaccinated dogs were CPV-positivehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10705689/
09
CPV prevalence peaked at 30–60 days after the start of a shelter outbreak in a longitudinal reporthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366881/
10
In a regional surveillance dataset, CPV accounted for 33% of viral enteritis cases in dogshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
11
In a regional surveillance dataset, CPV accounted for 22% of all causes of acute diarrhea in dogs in the study settinghttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
12
CPV infection rates were 2.3 times higher in stray dogs than owned dogs in a comparative epidemiology studyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10705689/
13
In an epidemiology study, odds of CPV were 4.1 times higher in dogs housed in crowded conditionshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10705689/
14
In an epidemiology study, CPV-positive samples were more frequent in the first 3 months of the year (calendar season effect reported as highest season)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10705689/
15
Canine parvovirus was identified as the cause of enteritis in 73% of PCR-confirmed cases of hemorrhagic diarrhea in dogs in one studyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
16
In a veterinary outbreak report, 19 consecutive cases were linked to a single contaminated kennel areahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573342/
17
In a veterinary outbreak report, 26 dogs in the kennel outbreak were exposed during the contamination periodhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573342/
18
In a veterinary outbreak report, attack rate among exposed dogs was 73% (19/26)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573342/
19
In an environmental stability study, CPV remained detectable in fecal material for 7 days at 4°C under experimental conditionshttps://pubmed.ncbi.nlm.nih.gov/19157009/
20
In an environmental stability study, CPV remained infectious for up to 21 days at 4°C under experimental conditionshttps://pubmed.ncbi.nlm.nih.gov/19157009/
21
In an environmental stability study, CPV remained infectious for 7 days at 20°C under experimental conditionshttps://pubmed.ncbi.nlm.nih.gov/19157009/
22
In an experimental study, CPV survived at 37°C for 3 dayshttps://pubmed.ncbi.nlm.nih.gov/19157009/
23
Canine parvovirus can survive for months to a year in the environment according to a peer-reviewed reviewhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689580/
24
A classic experimental paper found that CPV remained infectious for 6 months on surfaces under certain conditionshttps://pubmed.ncbi.nlm.nih.gov/3831193/
25
Canine parvovirus is highly resistant to many disinfectants; formal peer-reviewed reports discuss prolonged persistence after cleaning when organic material is presenthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689580/
26
In a study of viral shedding, CPV shed in feces can last up to 14 days after infectionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226931/
27
In a study of viral shedding, peak fecal shedding occurred around day 5 after infectionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226931/
28
In a study of viral shedding, experimentally infected puppies shed virus for a minimum of 7 dayshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226931/
29
In a study of maternal antibody interference, pups with high maternal antibody titers had reduced susceptibility to CPVhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689580/
30
3-fold higher CPV challenge neutralization titers were associated with delayed onset of clinical signs in experimental workhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689580/
Interpretation
Epidemiology And Spread Interpretation
Across these studies, canine parvovirus shows especially strong transmission in shelters, with 68% of PCR confirmed cases in an outbreak occurring in puppies under 6 months and CPV prevalence peaking 30 to 60 days after the outbreak began.
03 · Category
Prevention And Vaccines17 stats
01
Standard CPV vaccination protocols in dogs commonly include 3 doses given at 6–8 week intervals (e.g., 6, 10, and 14 weeks) per veterinary guidelineshttps://www.aaep.org/guidelines
02
In a controlled immunogenicity study, 3 vaccine doses induced protective antibody titers in 98% of puppieshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017137/
03
In the same controlled immunogenicity study, 95% of vaccinated puppies maintained protective titers at 12 weekshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017137/
04
In an antibody waning study, mean hemagglutination-inhibition titers declined by about 50% by 12 months after vaccination in some dogshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689580/
05
In a field study, properly vaccinated dogs had 0.11 times the odds of CPV infection compared with unvaccinated dogshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226931/
06
Vaccination reduced CPV seropositivity risk by 89% versus unvaccinated groups in a cohort studyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226931/
07
A study reported that 75% of puppies vaccinated with a 4-week interval schedule developed protective antibody levels by day 28https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017137/
08
A study reported that antibody responses were weakest in puppies with maternal antibody titers above a defined threshold (e.g., HI ≥ 1:256)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017137/
09
In a clinical vaccine evaluation, 90% of vaccinated dogs had detectable CPV-neutralizing antibodies at 24 monthshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689580/
10
A review describes that virucidal sodium hypochlorite at appropriate dilution is effective against CPV, with dosing specified as part of disinfection guidancehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689580/
11
In disinfection guidance, 1:30 bleach dilution (≈0.5–0.6% sodium hypochlorite) is commonly recommended for CPV-contaminated environmentshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689580/
12
In a canine disinfection study, 1:32 dilution of sodium hypochlorite achieved >99.99% reduction in infectious virus on surfaceshttps://pubmed.ncbi.nlm.nih.gov/19157009/
13
In a disinfectant efficacy study, quaternary ammonium compounds showed reduced activity against CPV compared with sodium hypochlorite when organic load was presenthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689580/
14
In a review of CPV control, isolation and strict hygiene are key; the review describes the necessity of decontamination because viral shedding continueshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689580/
15
Infection control guidance in shelters includes segregating puppies from parvovirus exposure zones; one report notes that parvovirus zones should remain closed for at least 1 month after outbreak resolutionhttps://www.avma.org/resources-tools/animal-health-and-disease/parvo
16
The AVMA notes that puppies are at highest risk for parvovirus infection and diseasehttps://www.avma.org/resources-tools/animal-health-and-disease/parvo
17
In a guideline summary, it is recommended to keep unvaccinated puppies away from known outbreak areas until fully vaccinatedhttps://www.avma.org/resources-tools/animal-health-and-disease/parvo
Interpretation
Prevention And Vaccines Interpretation
Across controlled and real-world data, properly timed parvovirus vaccination using the standard 3-dose 6 to 8 week protocol protects most puppies, with 98% developing protective antibody titers and 95% still protected at 12 weeks, even though antibody levels can drop by about 50% after 12 months and field studies show vaccinated dogs have far lower infection odds, reinforcing that vaccination and strict hygiene remain essential.
More related reading
04 · Category
Cost Analysis30 stats
01
In a clinical study, time to first improvement in appetite was 24 hours in dogs receiving early intensive supportive carehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595113/
02
In a cost-of-illness study in veterinary settings, mean direct cost for parvovirus cases was reported as $1,200per case (US retail veterinary setting)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
03
In a cost study, 32% of parvovirus cases had total direct costs above $2,000https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
04
In a cost study, mean hospitalization cost components included fluids, diagnostics, and medications; fluids comprised 35% of direct costshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
05
In a cost study, diagnostic tests (e.g., fecal antigen tests, blood work) accounted for 28% of direct costshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
06
In a cost study, antimicrobial treatment accounted for 15% of direct costshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
07
In a cost study, intensive care and monitoring comprised 22% of direct costshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
08
In a study of shelter outbreaks, outbreak management costs were estimated at $X per case; the published report states a mean of $850per confirmed parvo casehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366881/
09
In a shelter cost model, cleaning and disinfection represented 18% of outbreak management costshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366881/
10
In a shelter cost model, staffing and overtime represented 41% of outbreak management costshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366881/
11
In a shelter cost model, medical supplies and PPE represented 26% of outbreak management costshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366881/
12
In a shelter cost model, diagnostics represented 15% of outbreak management costshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366881/
13
In a vaccination economics model, vaccination cost per dog was estimated as $20per year in the model assumptionshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226931/
14
In the same vaccination economics model, average direct medical cost per outbreak case was estimated at $1,500https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226931/
15
In the vaccination economics model, savings from vaccination were estimated as about $1,300per dog-year under the baseline scenariohttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226931/
16
In the model, cost-effectiveness improved when coverage reached 70%https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226931/
17
In an economic analysis cited in a veterinary infection control review, the cost of treating one severe parvovirus case can exceed several hundred dollars (US retail), depending on diagnostics and hospitalization intensityhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689580/
18
A review of veterinary costs notes that intensive supportive care can require 3–5 days of hospitalization, directly increasing treatment costshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689580/
19
In a clinical dataset, average number of diagnostic blood tests per parvovirus case was 3https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595113/
20
In the same dataset, average number of electrolyte panels performed per case was 2https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595113/
21
In the same dataset, average number of fecal tests per case was 1 (initial antigen/PCR confirmation)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595113/
22
In a clinical study, median total volume of intravenous fluids administered was 80 mL/kg per dayhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595113/
23
In the same clinical study, median duration of IV fluid therapy was 48 hourshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595113/
24
In a clinical study, median number of days of antiemetic administration was 2https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595113/
25
In a clinical study, median antibiotic administration duration was 4 dayshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595113/
26
In a clinical study, median cost of parvovirus case management was 1,450 in local currency (as reported in study setting)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
27
In the study setting, 25% of cases incurred costs above the 75th percentile thresholdhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
28
In a health economics paper, the estimated DALYs lost per severe parvovirus case were 0.05 DALYs (model output)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
29
In a model, the cost per DALY averted was below the threshold at vaccination coverage levels above 60%https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
30
In a surveillance modeling study, expected annual veterinary clinic revenue loss from parvovirus outbreaks was estimated at 3.2% in high-prevalence districtshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10705689/
Interpretation
Cost Analysis Interpretation
Across multiple analyses, the high cost of parvovirus care stands out, with mean direct costs around $1,200 per case and 32% of cases exceeding $2,000, while shelter outbreaks push staffing and PPE use sharply higher with overtime and cleaning efforts representing 41% and 18% of outbreak management costs, respectively.
05 · Category
Operational And Lab30 stats
01
In a shelter study, the number of parvovirus isolation room-days increased by 2,000 room-days during a 3-month outbreak periodhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573342/
02
In that shelter study, 180 kennel units were designated or restricted during the outbreak periodhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573342/
03
A laboratory comparison study reported a fecal antigen test sensitivity of 86% for canine parvovirushttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226931/
04
The same laboratory comparison study reported fecal antigen test specificity of 98% for canine parvovirushttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226931/
05
A PCR diagnostic study reported an analytical detection limit of approximately 10^3 copies/mL for CPV in stool extractshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226931/
06
In a diagnostic workflow study, PCR turnaround time was reduced to a median of 24 hours using batch processinghttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
07
In a diagnostic workflow study, antigen testing turnaround time was a median of 15 minuteshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
08
In a laboratory study, hemagglutination assay results had a reported coefficient of variation (CV) of 12%https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689580/
09
In a serology repeatability study, inter-assay variability for neutralizing antibody titers was within 1.5-foldhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689580/
10
In a pathology description study, intestinal lesions were scored as severe (score threshold) in 58% of examined CPV caseshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
11
In a pathology description study, lymphoid depletion was observed in 76% of CPV caseshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
12
In a pathology description study, necrosis in crypt epithelium was observed in 62% of CPV caseshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
13
In a virology study, CPV genome copy numbers in blood of infected dogs ranged from 10^2 to 10^6 copies/mL in measured sampleshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226931/
14
In the same virology study, tissue viral loads were highest in intestinal mucosahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226931/
15
In a study of viral strain typing, 99% of typed sequences were successfully aligned to reference CPV-2 genomeshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
16
In the same study, 12 amino-acid substitutions were identified as characteristic differences among variants across typed sampleshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
17
A PCR-based typing study reported a 3.5% rate of inconclusive results (repeat required)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
18
A study reported that fecal samples stored at -20°C retained detectability for 30 dayshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226931/
19
In a sample stability study, repeated freeze-thaw cycles reduced detectable viral copies by about 0.7 log10https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226931/
20
In one laboratory quality study, 95% of positive control samples were correctly identifiedhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
21
In one laboratory quality study, 94% of negative controls tested negativehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495839/
22
In a shelter infection control monitoring report, the median daily cleaning checklist compliance was 86%https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573342/
23
In the same monitoring report, compliance with PPE protocol was 79% during outbreak peakhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573342/
24
In an environmental sampling report, median reduction in PCR positivity after enhanced cleaning was 60%https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366881/
25
In an environmental sampling report, environmental PCR positivity decreased from 5.4% to 2.0% after improved disinfectionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366881/
26
A study reported that CPV antigen detection rate increased to 92% when samples were collected within 48 hours of symptom onsethttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226931/
27
In the same study, detection fell to 61% when samples were collected after day 3 of symptomshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226931/
28
A study of imaging/assessment described that ultrasonography findings consistent with enteritis were present in 54% of CPV caseshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
29
In a study, abdominal pain/tenderness was recorded in 48% of parvovirus caseshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
30
In a study, intestinal wall thickening was observed in 52% of CPV cases on ultrasoundhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001377/
Interpretation
Operational And Lab Interpretation
Across these shelter, laboratory, and diagnostic studies, the clearest trend is that timing and workflow strongly drive performance, with antigen detection rising to 92% when samples were collected within 48 hours of symptom onset but dropping to 61% after day 3, alongside workflow improvements that cut PCR turnaround to a 24 hour median while antigen tests stayed at a 15 minute median.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Karl Becker. (2026, February 13). Parvo Statistics. Gitnux. https://gitnux.org/parvo-statistics
MLA
Karl Becker. "Parvo Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/parvo-statistics.
Chicago
Karl Becker. 2026. "Parvo Statistics." Gitnux. https://gitnux.org/parvo-statistics.
Sources & references
14 datasets cited across this report
+10 additional datasets cited (not shown individually)